EMA Panel Backs Quarterly Vaginal Ring for HIV Prevention

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for a new 100-mg strength of the dapivirine vaginal ring (dapivirine) for adolescents and women aged 16 years or older to reduce their risk of acquiring HIV -1 during vaginal intercourse. If authorized, the new strength would extend ring replacement from monthly to every 3 months. Mechanism and Dosing Dapivirine is a non-nucleoside reverse transcriptase inhibitor that blocks reverse transcriptase, an enzyme essential for HIV replication within infected cells and viral dissemination. By inhibiting this enzyme, dapivirine helps prevent viral replication following exposure. The previously authorized 25-mg ring is a silicone device that gradually releases dapivirine, an antiviral agent, over 1 month. Women remove it after 4 weeks and insert a new one immediately. The 100-mg strength is designed for replacement every 3 months. Supporting Evidence for Extended Duration Supporting evidence includes MTN-036/IPM-047, a phase 1 randomized trial in 49 HIV-negative participants that compared two 3-month dapivirine vaginal rings containing 100 mg or 200 mg with the monthly 25-mg ring, with each ring used over a 13-week period. Investigators assessed safety, pharmacokinetics, adherence, and acceptability. The proportion of participants experiencing grade 2 or higher genitourinary adverse events or grade 3 or higher adverse events did not differ between the extended-duration and monthly ring groups. Dapivirine concentrations in plasma and cervicovaginal fluid were higher with the extended-duration rings than with the monthly formulation, supporting further evaluation of the 3-month approach. Most participants (82%) demonstrated full adherence, maintaining continuous ring insertion without discontinuations or gaps in use. Adherence did not differ between the monthly and 3-month rings. Participants generally found the rings acceptable, with a median acceptability score of 8 on a 10-point Likert scale. Overall, the extended-duration rings were well tolerated and achieved higher dapivirine concentrations than the monthly formulation, supporting further evaluation of 3-month rings for HIV prevention. Safety and Contraindications The most common adverse events, which may affect more than 1 in 20 users, include urinary tract infection, vaginal discharge, vulvovaginal pruritus, vulvovaginitis , and pelvic pain. The dapivirine vaginal ring must not be used by women with unknown or positive HIV status. Global Regulatory Collaboration The CHMP evaluated the 100-mg ring under the EU-Medicines for all (EU-M4all) pathway, a mechanism enabling the EMA to assess medicines intended for markets outside the EU while strengthening global regulatory capacity. Specialists from the World Health Organization alongside national regulatory authorities from Kenya, South Africa, and Zambia participated in the scientific review to support public health rollout in high-burden regions. Detailed recommendations for product use will be published on the EMA website after the European Commission’s decision on the marketing authorization. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.